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Abstract
Vaccines using dendritic cells (DCs) harboring leukemic antigens to stimulate T cells is a possible treatment of acute
myeloid leukemia (AML). Limitations of breaking tolerance to leukemic cells and lack of specific activation of T cell–
mediated cytotoxicity may explain the discouraging clinical results with this approach. To break self-tolerance against
AML cells, we loaded DCs with AML antigens and a bifunctional small interference (si) RNA targeting interleukin (IL)
10 and simultaneously activating toll-like receptors (TLRs). In vitro, this active siRNA inhibited (P < .05) IL-10 produc-
tion by silencing the IL-10 gene in DCs. The active siRNA stimulated production of tumor necrosis factor α, implying
activation of TLRs. Vaccination in a nonimmunogenic rat model mimicking human AML with the loaded DCs in-
duced a substantial and specific T-cell cytotoxicity. Leukemic rats treated with the active siRNA lived longer and
had markedly less leukemic cell mass infiltrating their bone marrow compared with rats given inactive siRNA (P <
.05). Furthermore, compared with inactive siRNA treatment, the active siRNA led to significantly less extramedullar
leukemic dissemination, evidenced by reduced matrix metalloproteinase activity and smaller spleens. Our data dem-
onstrate that this bifunctional siRNA may work as an immunomodulatory drug with antileukemic properties.
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Introduction
The recognition that the graft-versus-leukemia effect is important
points to immunomodulation as possible treatment of acute myeloid
leukemia (AML). In addition to induction of graft-versus-leukemia,
vaccines have been developed, but often with dismal results [1]. This
may be due to limitations of breaking tolerance to leukemic cells and/
or insufficient activation of high-affinity cytotoxic T cells [2].
Toll-like receptor (TLR) ligands can break tolerance to self-antigens
and promote immune response to tumor antigens, as well as induce
dendritic cell (DC) differentiation, and TLR ligands provide signals
necessary for activation of innate and adaptive immune responses [3].
Although TLR ligands elicit immune responses, they also induce ex-
pression of DC-derived immunosuppressive cytokines, like interleukin
(IL) 10, which can influence T cell–mediated immunity [4]. In addi-
tion, IL-10 has been associated with the development of tolerogenic
DCs [4]. This inhibitory feedback mechanism may hamper effective
immunity against tumor cells. Moreover, whereas IL-10 reduces the
production of proleukemic cytokines in cultured AML blast cells, such
an antileukemic effect in patients has been challenged [5]. Devel-
opment of agents that stimulate DC maturation through TLRs and
simultaneously inhibit immunosuppression may thus facilitate design
of effective cancer vaccines in AML.
Among the gene-silencing approaches, RNA interference offers
a novel opportunity for posttranscriptional inhibition of immuno-
suppressive factor expression in vitro and in vivo. Initially, the RNA
interference pathway was thought to be nonfunctional in mammalian
cells, where double-stranded RNA longer than 30 nucleotides induces
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a nonspecific antiviral response known as the interferon (IFN) pathway.
It has been reported that small interference (si) RNA, when introduced
into mammalian cells, did not trigger the IFN pathway but effec-
tively silenced gene expression in a sequence-dependent manner [6].
However, we have shown that certain siRNA sequences can bind to
TLRs and trigger the activation of innate immunity [7,8]. We recently
designed a bifunctional siRNA that cleaves target messenger RNA
and increases the production of cytokines through TLRs [9]. This
siRNA efficiently inhibited IL-10 gene expression in cultured DCs and
primed T cells, thus suggesting its possible usefulness as an immuno-
modulatory drug.
Here we examined whether self-tolerance to leukemic antigens could
be broken by this siRNAwhen used as adjuvant in a nonimmunogenic
rat model of human AML [10]. We show that this novel DC-based
vaccine could inhibit the development and progression of neoplastic
blood cells.
Materials and Methods
siRNA and Leukemic Cell Protein Lysate
To activate TLRs, the anti–IL-10 siRNA was designed to contain a
significant number of uridines (Eurogentec, Seraing, Belgium) [11]. A
2′-O-methyl uridine–modified siRNA targeting mouse basigin was
used as an inactive control because this modification abolishes siRNA
sensing by TLRs [12]. The target site sequences of the siRNA were
as follows:
active siRNA, 5′-ACGCUGUCAUCGAUUUCUC-3′
inactive (control) siRNA, 5′-GAGGCAAUCACCAAUAGCA-3′
Leukemic cells from the Brown Norwegian (BN) rat model of
human AML were suspended at a density of 1 × 107 cells/ml, frozen
at −80°C, and disrupted by four freeze-thaw cycles. Then the cell sus-
pensions were sonicated, and after that, the supernatants were passed
through a 0.2-μm filter.
Generation of DCs
Blood cells from healthy BN rats were separated according to density
before the monocytes were purified using plastic adherence and cul-
tured in complete RPMI medium supplemented with granulocyte-
macrophage colony-stimulating factor (50 ng/ml) and IL-4 (100 ng/ml)
to generate immature DCs. On day 5, these DCs were transfected with
either the active or the inactive siRNA (20 μg/2 × 106 cells) using
cationic liposomes (DOTAP; 20 μg/ml; Boehringer Mannheim,
Mannheim, Germany). In both cases, 50 μg of leukemic cell protein
extracts was added to the transfection mixture. Subsequent to overnight
incubation, cells were harvested, washed, and then immediately used
for immunization.
Assays of siRNA Effects in DCs
To test for siRNA-mediated anti–IL-10 activity, immature DCs (1 ×
106/ml) were transfected with siRNA (2 μg/transfection) using electro-
poration before stimulating with lipopolysaccharide (25 ng/ml) for
18 hours. We used ELISA kits (PromoKine, Heidelberg, Germany)
to measure IL-10 and tumor necrosis factor α (TNFα) in the super-
natants. IL-10 messenger RNA (mRNA) from DC was analyzed by re-
verse transcription–polymerase chain reaction using SYBR Green PCR
Master Mix (Invitrogen, Carlsbad, CA) and the ABI PRISM 7700
equipment (Applied Biosystems, Foster City, CA). Glyceraldehyde
phosphate dehydrogenase was used as an internal control gene. The
following primers were used:
IL-10 forward 5′-AAAAGCAAGGCAGTGGAGCA-3′ and re-
verse 5′-AAGGAGTTGCTCCCGTTAGC-3′ (product 200 bp)
GADH forward 5-CATGCCATCACTGCCACTCA-3′ and re-
verse 5′-GTTTCTCCAGGCGGCATGTC-3′ (product 200 bp).
The mRNA expressions was quantified by the comparative cycle
threshold method [13].
Transplantation Protocol
The protocol conformed to the national legislation and guidelines
(permission no. S-2006/30555). The animals were tested negative
for microbes [14]. We used the BN model of AML because it reliably
mimics several important features of human AML including develop-
ment and progression of the disease as well as response to chemotherapy
[10]. Syngeneic BN rats (n = 10 per group) were randomly assigned to
be injected subcutaneously with 2 million DCs transfected with either
active or inactive siRNA, and loaded with the leukemic lysate. One
week later (day 0), this procedure was repeated before we transplanted
the rats with leukemic cells [15]. We also included 10 untreated leuke-
mic rats as controls. The rats were killed with an intraperitoneal over-
dose of barbiturate when they developed obvious signs of disease.
Assays of Leukemia Development and Serum Cytokines
Bone marrow leukemic cellularity was assessed with antibody staining
of a leukemic cell–specific antigen and flow cytometry [16]. As a measure
of leukemic metastasis, we quantified serum matrix metalloproteinase
(MMP) with zymography [15]. Activation of T cell–mediated cyto-
toxicity was assessed by determination of 51Cr release [17].
Serum cytokines were measured using a Lincoplex Kit (Linco Re-
search, St Charles,MO) according to the instructions of themanufacturer
and as described elsewhere [18].
Statistics
Unless otherwise stated, values are medians (interquartile range). We
used 2-tailed Mann-Whitney or Kruskal-Wallis tests followed by the
Bonferroni correction, as appropriate. P < .05 was taken to indicate
statistical significance.
Results and Discussion
The Active siRNA Inhibits IL-10 and Stimulates TNFα in
Cultured DCs
To determine the IL-10 silencing potency of the active siRNA, we
analyzed the production of IL-10 sampled from cultured DCs. The
concentration of IL-10 in supernatants from DCs transfected with
active siRNAwas approximately five-fold reduced compared with those
given inactive siRNA or untransfected DCs (median 199 vs 1075 vs
1035 pg/ml, respectively, P < .01, n = 6 per group). In support of these
findings, DCs transfected with the active siRNA showed very low IL-10
mRNA levels compared with DCs transfected with the inactive siRNA
(Figure 1). We then investigated the immunostimulatory potential of
the active siRNA. Transfection of DCs with the active siRNA increased
the supernatant concentration of TNFα, a marker of TLRs stimula-
tion, approximately nine-fold compared with DCs transfected with
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the inactive siRNA or untransfected DCs (median 1353 vs 150 vs
194 pg/ml, P < .01, n = 6 per group). Addition of neutralizing anti–
IL-10 antibodies to transfected or untransfected DCs did not alter
the supernatant concentrations of either IL-10 or TNFα (data not
shown). Notably, DCs might have an additional level of self-/non–
self-discrimination that functions at the level of phagosomematurations
[19]. Therefore, conjugation of self-antigen and TLRs ligands through
liposomes is expected to improve immune response. We recently
identified several genes involved in different pathways such as antigen
presentation, cell motility, and endosome maturation induced by
immunostimulatory siRNA [12]. Moreover, these genetic analyses in-
dicated that the active siRNA most likely stimulated TLRs 7 and 8.
The Active siRNA Induces Specific T-Cell Cytotoxicity
To examine if DCs transfected with the active siRNA could induce a
T cell–specific response, rats were immunized with DCs loaded with
leukemic protein lysates and siRNA. T-cell cytotoxicity against leuke-
mic cells was determined 4 weeks later. Figure 2 shows that T cells from
rats given DCs with active siRNA had a profound increase in cytolytic
capacity compared with T cells from rats given DCs with inactive
siRNA, demonstrating induction of T cell–specific antileukemic activity.
Cytotoxicity from T cells sampled from healthy rats was similar to those
from rats given DCs transfected with inactive siRNA (data not shown).
Whereas anti–major histocompatibility complex (MHC) class II anti-
bodies had no effect (data not shown), anti–MHC class I antibodies
abrogated this response (Figure 2). Moreover, we could not detect any
antibody specifically directed against the leukemic protein lysates (data
not shown). Collectively, these findings further indicate the specificity
of the T cell–mediated cytotoxicity.
Dendritic Cells Harboring the Active siRNA Inhibit
Leukemogenesis in Rat AML
Given that self-tolerance can be broken by delivering a TLR signal
and blocking IL-10 expression in DC, we next examined whether
IL-10–silenced DCs would induce antileukemic immunity in vivo.
Kaplan-Meier analysis revealed a survival advantage among rats given
DCs transfected with active siRNA compared with those given DCs
transfected with inactive siRNA (Figure 3; P = .035, log-rank test).
Moreover, in rats treated with DCs transfected with active siRNA,
Figure 2. The active siRNA induced specific T-cell cytotoxicity. Lysis
of autologous leukemic cells were increased at all effector-to-target
cell ratios tested when T cells from leukemic rats treated with DCs
transfected with active siRNA (squares) were compared with those
given inactive siRNA (triangles). The specific lysis of autologous
leukemic cells given anti–MCH class I antibodies (circles) was neg-
ligible. MHC class I expression did not differ between untransfected
DCs or DCs transfected with active or inactive siRNA (data not
shown). T cells and target cells were harvested from blood and
spleen before further purification with monoclonal antibodies and
flow cytometric sorting. *P < .05. Values are mean and SEM,
n = 10 per group.
Figure 3. Increased survival on treatment with active siRNA. Leuke-
mic rats treated with DCs transfected with active siRNA (thick filled
line) lived longer compared with those given either inactive siRNA
(thin solid line) or with untreated rats (dashed line). n= 10 per group.
Figure 1. ThemRNA expression of IL-10 relative to that GAPDHwas
markedly reduced in DCs transfected with active compared with
inactive siRNA. Values are mean + SEM, n = 4, *P < .05.
Figure 4. The bone marrow leukemic cellularity was significantly
lower among rats treated with DCs transfected with the active siRNA
(triangles) compared with those given inactive siRNA (circles), or with
untreated rats (squares). Individual values are shown and are given
as percentages of the total number of nucleated cells. The horizontal
lines represent median values. n = 10 per group.
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median leukemic cell load constituted 55% of bone marrow cellular
content, a marked reduction compared with the 85% and 82% in
median leukemic cellularity in rats treated with DC transfected with
the inactive siRNA or in untreated leukemic rats, respectively (Fig-
ure 4). The spleen mass is a valid measure of leukemic dissemination
in this model [20]. Whereas median splenic weight among rats given
DCs transfected with inactive siRNA or untreated rats were 3.9 and
4.6 g, respectively, it was substantially lower (P < .05) in rats treated
with DCs transfected with active siRNA: 2.6 g (Figure 5). Activation
of MMP is required for extravasation of leukemic cells [21]. Further
supporting the inhibitory effect of the active siRNA on leukemic dis-
semination, the median MMP activity in rats given DCs transfected
with active siRNA was only 63.3% (P < .05) of that measured among
untreated rats, whereas the corresponding percentage was 94 among
rats given DCs transfected with the inactive siRNA (Figure 6).
To further establish the specificity of DCs transfected with the
active siRNA in reducing IL-10 concomitant with activation of TLRs,
we measured selected cytokines involved in an inflammatory reaction.
Table 1 shows that the serum concentrations of TNFα and IFN-γ,
but not of IL-1β, were increased in rats injected with DCs transfected
with active siRNA compared with those given DCs transfected with
inactive siRNA. Furthermore, the serum concentrations of IL-10 were
almost halved in rats treated with DCs transfected with active siRNA
compared with those given DCs transfected with inactive siRNA,
whereas those of IL-13, another immunosuppressive cytokine, re-
mained similar in both groups. These data further substantiate the spe-
cific anti–IL-10 effect of the active siRNA as well as the binding of the
active siRNA to TLRs 7/8.
There are some limitations to this study. First, we adopted a pre-
ventive strategy in relation to the development of leukemia to test the
efficacy of the siRNA treatment. We realize that this treatment regi-
men should next be tested in already established disease. Second,
although some survival benefit was detected, it was small. We there-
fore believe that the siRNA treatment might be best suited as sup-
plementary to other treatment options, for example, transplantation.
Moreover, it could also be valuable for patients that cannot tolerate
intensive treatment regimens.
To summarize, the siRNA efficiently reduced IL-10 production by
silencing its gene in DCs. In addition, transfection of DCs with the
siRNA enhanced production of TNFα, indicating stimulation of
TLRs 7/8. Importantly, vaccination with DCs harboring this siRNA
and leukemic antigens activated T cell–mediated killing of leukemic
cells as well as enhanced survival and reduced the leukemic cell burden
and metastasis in a rat model of AML. It has been reported that siRNA
directed at IL-10 can modulate DCs to stimulate T cells in vitro
[22,23]. However, the present study is the first to demonstrate a
combined immunoinhibitory and immunostimulatory effect of DC
siRNA in an in vivo model of human malignancy. Hence, our study
demonstrates that the use of a bifunctional siRNA in a vaccine setting
can break tolerance to leukemic cells and stimulate specific T-cell
cytotoxicity, and thus act as an immunomodulatory drug with anti-
leukemic properties.
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